JP6895752B2 - ニコチン酸および/またはニコチンアミドを含む、腸内微生物叢を改変することにより血中脂質レベルに有益に影響を及ぼすための医薬組成物 - Google Patents
ニコチン酸および/またはニコチンアミドを含む、腸内微生物叢を改変することにより血中脂質レベルに有益に影響を及ぼすための医薬組成物 Download PDFInfo
- Publication number
- JP6895752B2 JP6895752B2 JP2016538751A JP2016538751A JP6895752B2 JP 6895752 B2 JP6895752 B2 JP 6895752B2 JP 2016538751 A JP2016538751 A JP 2016538751A JP 2016538751 A JP2016538751 A JP 2016538751A JP 6895752 B2 JP6895752 B2 JP 6895752B2
- Authority
- JP
- Japan
- Prior art keywords
- nicotinamide
- nicotinic acid
- treatment
- prevention
- release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 title claims description 297
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 title claims description 253
- 235000005152 nicotinamide Nutrition 0.000 title claims description 169
- 239000011570 nicotinamide Substances 0.000 title claims description 169
- 229960003512 nicotinic acid Drugs 0.000 title claims description 155
- 229960003966 nicotinamide Drugs 0.000 title claims description 117
- 210000004369 blood Anatomy 0.000 title claims description 64
- 239000008280 blood Substances 0.000 title claims description 64
- 150000002632 lipids Chemical class 0.000 title claims description 60
- 244000005709 gut microbiome Species 0.000 title claims description 47
- 239000008194 pharmaceutical composition Substances 0.000 title description 49
- 230000000051 modifying effect Effects 0.000 title description 6
- 239000011664 nicotinic acid Substances 0.000 claims description 103
- 235000001968 nicotinic acid Nutrition 0.000 claims description 103
- 239000000203 mixture Substances 0.000 claims description 100
- 238000011282 treatment Methods 0.000 claims description 70
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 67
- 239000013543 active substance Substances 0.000 claims description 64
- 210000002966 serum Anatomy 0.000 claims description 56
- 230000002265 prevention Effects 0.000 claims description 48
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 40
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 35
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 34
- 230000009286 beneficial effect Effects 0.000 claims description 33
- 238000013270 controlled release Methods 0.000 claims description 32
- 210000001072 colon Anatomy 0.000 claims description 31
- 210000000813 small intestine Anatomy 0.000 claims description 30
- 230000003111 delayed effect Effects 0.000 claims description 29
- 210000003405 ileum Anatomy 0.000 claims description 22
- 108010010234 HDL Lipoproteins Proteins 0.000 claims description 17
- 102000015779 HDL Lipoproteins Human genes 0.000 claims description 17
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 15
- 241001465754 Metazoa Species 0.000 claims description 15
- 210000004185 liver Anatomy 0.000 claims description 15
- 201000001320 Atherosclerosis Diseases 0.000 claims description 14
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 14
- 229940000425 combination drug Drugs 0.000 claims description 14
- 239000002552 dosage form Substances 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 13
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 claims description 11
- XJLXINKUBYWONI-NNYOXOHSSA-O NADP(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-O 0.000 claims description 11
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 9
- 208000008589 Obesity Diseases 0.000 claims description 9
- 235000020824 obesity Nutrition 0.000 claims description 9
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 8
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 8
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 8
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 230000001965 increasing effect Effects 0.000 claims description 7
- 229950006238 nadide Drugs 0.000 claims description 7
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 230000006806 disease prevention Effects 0.000 claims description 5
- 239000000543 intermediate Substances 0.000 claims description 5
- 239000002207 metabolite Substances 0.000 claims description 5
- 230000004048 modification Effects 0.000 claims description 5
- 238000012986 modification Methods 0.000 claims description 5
- 230000001934 delay Effects 0.000 claims description 4
- 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 claims description 4
- -1 nicotinic acid ester Chemical class 0.000 claims description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 3
- 230000036765 blood level Effects 0.000 claims description 3
- 230000000069 prophylactic effect Effects 0.000 claims description 3
- YGPSJZOEDVAXAB-UHFFFAOYSA-N (R)-Kynurenine Natural products OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 claims description 2
- VCKPUUFAIGNJHC-LURJTMIESA-N 3-hydroxy-L-kynurenine Chemical compound NC1=C(O)C=CC=C1C(=O)C[C@H]([NH3+])C([O-])=O VCKPUUFAIGNJHC-LURJTMIESA-N 0.000 claims description 2
- YGPSJZOEDVAXAB-QMMMGPOBSA-N L-kynurenine Chemical compound OC(=O)[C@@H](N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-QMMMGPOBSA-N 0.000 claims description 2
- BYHJHXPTQMMKCA-QMMMGPOBSA-N N-formyl-L-kynurenine Chemical compound [O-]C(=O)[C@@H]([NH3+])CC(=O)C1=CC=CC=C1NC=O BYHJHXPTQMMKCA-QMMMGPOBSA-N 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- KACPVQQHDVBVFC-OIFXTYEKSA-N cis,cis-2-amino-3-(3-oxoprop-1-enyl)but-2-enedioic acid Chemical compound OC(=O)C(/N)=C(/C(O)=O)\C=C/C=O KACPVQQHDVBVFC-OIFXTYEKSA-N 0.000 claims description 2
- JOUIQRNQJGXQDC-ZYUZMQFOSA-L nicotinate D-ribonucleotide(2-) Chemical compound O1[C@H](COP([O-])([O-])=O)[C@@H](O)[C@@H](O)[C@@H]1[N+]1=CC=CC(C([O-])=O)=C1 JOUIQRNQJGXQDC-ZYUZMQFOSA-L 0.000 claims description 2
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 claims description 2
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 claims description 2
- GJAWHXHKYYXBSV-UHFFFAOYSA-N quinolinic acid Chemical compound OC(=O)C1=CC=CN=C1C(O)=O GJAWHXHKYYXBSV-UHFFFAOYSA-N 0.000 claims description 2
- XLGFYNZFLFCWLI-UHFFFAOYSA-N 3-hydroxyanthracene-1-carboxylic acid Chemical compound C1=CC=C2C=C3C(C(=O)O)=CC(O)=CC3=CC2=C1 XLGFYNZFLFCWLI-UHFFFAOYSA-N 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 49
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 40
- 201000010099 disease Diseases 0.000 description 36
- 230000009885 systemic effect Effects 0.000 description 30
- 230000002159 abnormal effect Effects 0.000 description 29
- 239000008187 granular material Substances 0.000 description 27
- 229940079593 drug Drugs 0.000 description 25
- 239000003814 drug Substances 0.000 description 25
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 24
- 230000000694 effects Effects 0.000 description 24
- 239000002775 capsule Substances 0.000 description 22
- 229920000642 polymer Polymers 0.000 description 22
- 235000015872 dietary supplement Nutrition 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 19
- 230000003993 interaction Effects 0.000 description 19
- 210000000936 intestine Anatomy 0.000 description 18
- 244000005706 microflora Species 0.000 description 18
- 230000000813 microbial effect Effects 0.000 description 16
- 238000000034 method Methods 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 15
- 235000005911 diet Nutrition 0.000 description 14
- 210000001035 gastrointestinal tract Anatomy 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 13
- 239000003826 tablet Substances 0.000 description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 230000037213 diet Effects 0.000 description 12
- 230000000968 intestinal effect Effects 0.000 description 12
- 229920003141 Eudragit® S 100 Polymers 0.000 description 11
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 11
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 11
- 229920003139 Eudragit® L 100 Polymers 0.000 description 10
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 10
- 238000000576 coating method Methods 0.000 description 10
- 230000002496 gastric effect Effects 0.000 description 10
- 239000008185 minitablet Substances 0.000 description 10
- 229920003143 Eudragit® FS 30 D Polymers 0.000 description 9
- 108010007622 LDL Lipoproteins Proteins 0.000 description 9
- 102000007330 LDL Lipoproteins Human genes 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 239000011248 coating agent Substances 0.000 description 9
- 235000013305 food Nutrition 0.000 description 9
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 9
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 9
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 9
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 9
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 9
- 230000000670 limiting effect Effects 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 229920003138 Eudragit® L 30 D-55 Polymers 0.000 description 8
- 241000736262 Microbiota Species 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 229920001800 Shellac Polymers 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 239000007903 gelatin capsule Substances 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 239000004208 shellac Substances 0.000 description 8
- 229940113147 shellac Drugs 0.000 description 8
- 235000013874 shellac Nutrition 0.000 description 8
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000001856 Ethyl cellulose Substances 0.000 description 7
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 7
- 230000001684 chronic effect Effects 0.000 description 7
- 229920003045 dextran sodium sulfate Polymers 0.000 description 7
- 235000019325 ethyl cellulose Nutrition 0.000 description 7
- 229920001249 ethyl cellulose Polymers 0.000 description 7
- 235000012041 food component Nutrition 0.000 description 7
- 239000005417 food ingredient Substances 0.000 description 7
- 239000006041 probiotic Substances 0.000 description 7
- 235000018291 probiotics Nutrition 0.000 description 7
- 230000036962 time dependent Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- 206010009887 colitis Diseases 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 208000030159 metabolic disease Diseases 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000009498 subcoating Methods 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 5
- 241000792859 Enema Species 0.000 description 5
- 125000002707 L-tryptophyl group Chemical group [H]C1=C([H])C([H])=C2C(C([C@](N([H])[H])(C(=O)[*])[H])([H])[H])=C([H])N([H])C2=C1[H] 0.000 description 5
- 230000009102 absorption Effects 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 239000007920 enema Substances 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 239000004531 microgranule Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 208000004232 Enteritis Diseases 0.000 description 4
- 229920003134 Eudragit® polymer Polymers 0.000 description 4
- 229920003081 Povidone K 30 Polymers 0.000 description 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 4
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000007922 dissolution test Methods 0.000 description 4
- 229940095399 enema Drugs 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 208000020832 chronic kidney disease Diseases 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 3
- 229940038472 dicalcium phosphate Drugs 0.000 description 3
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 230000002550 fecal effect Effects 0.000 description 3
- 229960005436 inositol nicotinate Drugs 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000003094 microcapsule Substances 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- MFZCIDXOLLEMOO-GYSGTQPESA-N myo-inositol hexanicotinate Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](OC(=O)C=2C=NC=CC=2)[C@@H](OC(=O)C=2C=NC=CC=2)[C@@H]1OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)C(=O)C1=CC=CN=C1 MFZCIDXOLLEMOO-GYSGTQPESA-N 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000004962 physiological condition Effects 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229940068968 polysorbate 80 Drugs 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 229960004799 tryptophan Drugs 0.000 description 3
- ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 description 3
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 102100022595 Broad substrate specificity ATP-binding cassette transporter ABCG2 Human genes 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 229920003136 Eudragit® L polymer Polymers 0.000 description 2
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010019851 Hepatotoxicity Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108010090306 Member 2 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 description 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 2
- 108091006731 SLCO1B1 Proteins 0.000 description 2
- 102100027233 Solute carrier organic anion transporter family member 1B1 Human genes 0.000 description 2
- 229930003537 Vitamin B3 Natural products 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 239000007931 coated granule Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000004815 dispersion polymer Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 239000013583 drug formulation Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 231100000304 hepatotoxicity Toxicity 0.000 description 2
- 230000007686 hepatotoxicity Effects 0.000 description 2
- 208000008384 ileus Diseases 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- NXFFJDQHYLNEJK-CYBMUJFWSA-N laropiprant Chemical compound C=1([C@@H](CC(O)=O)CCC=1C=1C=C(F)C=C(C2=1)S(=O)(=O)C)N2CC1=CC=C(Cl)C=C1 NXFFJDQHYLNEJK-CYBMUJFWSA-N 0.000 description 2
- 229950008292 laropiprant Drugs 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 229940033757 niaspan Drugs 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 238000001050 pharmacotherapy Methods 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 2
- 229920000193 polymethacrylate Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000012502 risk assessment Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 229960002855 simvastatin Drugs 0.000 description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000007940 sugar coated tablet Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 235000019160 vitamin B3 Nutrition 0.000 description 2
- 239000011708 vitamin B3 Substances 0.000 description 2
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 description 1
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 1
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 1
- 101150102415 Apob gene Proteins 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000186012 Bifidobacterium breve Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 229920003135 Eudragit® L 100-55 Polymers 0.000 description 1
- 229920003140 Eudragit® L 12,5 Polymers 0.000 description 1
- 229920003137 Eudragit® S polymer Polymers 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 230000002994 HDL blood level Effects 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 101000843809 Homo sapiens Hydroxycarboxylic acid receptor 2 Proteins 0.000 description 1
- 238000009015 Human TaqMan MicroRNA Assay kit Methods 0.000 description 1
- 102100030643 Hydroxycarboxylic acid receptor 2 Human genes 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010021024 Hypolipidaemia Diseases 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 102100032394 N-acetyltransferase 8 Human genes 0.000 description 1
- 101710092255 N-acetyltransferase 8 Proteins 0.000 description 1
- 238000013232 NAFLD rodent model Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029400 Nicotinic acid deficiency Diseases 0.000 description 1
- 208000002141 Pellagra Diseases 0.000 description 1
- ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 241000605861 Prevotella Species 0.000 description 1
- 241000192031 Ruminococcus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 235000019742 Vitamins premix Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 229920006318 anionic polymer Polymers 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 229940004120 bifidobacterium infantis Drugs 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000009850 completed effect Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
- 229960000815 ezetimibe Drugs 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 238000012395 formulation development Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000001295 genetical effect Effects 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000037189 immune system physiology Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000012009 microbiological test Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 125000000627 niacin group Chemical group 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Chemical compound CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000013116 obese mouse model Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- 229960002797 pitavastatin Drugs 0.000 description 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000000580 polymer-drug conjugate Substances 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000013615 primer Substances 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- STWNGMSGPBZFMX-UHFFFAOYSA-N pyridine-3-carboxamide Chemical compound NC(=O)C1=CC=CN=C1.NC(=O)C1=CC=CN=C1 STWNGMSGPBZFMX-UHFFFAOYSA-N 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 230000007727 signaling mechanism Effects 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- CMSGWTNRGKRWGS-NQIIRXRSSA-N torcetrapib Chemical compound COC(=O)N([C@H]1C[C@@H](CC)N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OCC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CMSGWTNRGKRWGS-NQIIRXRSSA-N 0.000 description 1
- 229950004514 torcetrapib Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229920003176 water-insoluble polymer Polymers 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
a)脂質代謝障害の治療および/または予防、
b)異脂肪血症の治療および/または予防、
c)好ましくは、肝臓脂肪含量を低減し、かつ/または血液および/もしくは血漿および/もしくは血清脂質レベルに有益に影響を及ぼすことによる、非アルコール性脂肪性肝疾患(NAFLD)の治療および/または予防、
d)好ましくは、肝臓脂肪含量を低減し、かつ/または血液および/もしくは血漿および/もしくは血清脂質レベルに有益に影響を及ぼすことによる、非アルコール性脂肪性肝炎(NASH)の治療および/または予防、
e)心血管疾患の治療および/または予防、
f)動脈硬化症の治療および/または予防、
g)アテローム性動脈硬化症の治療および/または予防、
h)代謝症候群の治療および/または予防、
i)肥満の治療および/または予防、
j)腸内微生物叢における好ましくないもしくは異常な変化もしくは不均衡、および/または腸内微生物叢と腸との間の相互作用の低下に部分的に、または全体的に起因する、好ましくない、または異常な、または不均衡な血液および/または血漿および/または血清脂質レベルを特徴とする他の疾患の治療および/または予防。
a)脂質代謝障害の治療および/または予防、
b)異脂肪血症の治療および/または予防、
c)好ましくは、肝臓脂肪含量を低減し、かつ/または血液および/もしくは血漿および/もしくは血清脂質レベルに有益に影響を及ぼすことにより、非アルコール性脂肪性肝疾患(NAFLD)の治療および/または予防、
d)好ましくは、肝臓脂肪含量を低減し、かつ/または血液および/もしくは血漿および/もしくは血清脂質レベルに有益に影響を及ぼすことにより、非アルコール性脂肪性肝炎(NASH)の治療および/または予防、
e)心血管疾患の治療および/または予防、
f)動脈硬化症の治療および/または予防、
g)アテローム性動脈硬化症の治療および/または予防、
h)代謝症候群の治療および/または予防、
i)肥満の治療および/または予防、
j)腸内微生物叢における好ましくない、または異常な変化、または不均衡、および/または腸内微生物叢と腸との間の相互作用の低下に部分的に、または完全に起因する、好ましくない、または異常な、または不均衡な血液および/または血漿および/または血清脂質レベルを特徴とする他の疾患の治療および/または予防。
− グループ1:ミニ錠剤なしの低Trp/Nia/NAM食餌(対照)。
− グループ2:制御放出NAMミニ錠剤を食餌中に均一に分散させた(最終用量:マウス1匹1日あたり2.5gの食餌摂取に基づいて約60mg/kg体重)。
Claims (14)
- 腸内微生物叢の改変に用いられる組成物であり、
ニコチン酸;
ニコチンアミド;
ニコチン酸エステル、ニコチンアミドアデニンジヌクレオチド(NAD)、およびニコチンアミドアデニンジヌクレオチドリン酸(NADP)から選択される、動物または人の体内でニコチン酸またはニコチンアミドに変換される化合物;
N−ホルミルキヌレニン、L−キヌレニン、3−ヒドロキシ−L−キヌレニン、3−ヒドロキシアントラニル酸、2−アミノ−3−カルボキシムコン酸セミアルデヒド、キノリネート、およびベータ−ニコチネートD−リボヌクレオチドから選択される、NADまたはNADPの生合成における中間体;
またはこれらの組合せ
から選択される活性物質を含み、
改変しようとする腸内微生物叢が位置する、下部小腸、回腸終末部、および/または結腸において局部的に有効であるように活性物質を放出し、かつ、
脂質代謝障害;
異脂肪血症;
非アルコール性脂肪性肝疾患(NAFLD)、非アルコール性脂肪性肝炎(NASH);
心血管疾患;
動脈硬化症;
アテローム性動脈硬化症;
代謝症候群;および
肥満;からなる群から選択される疾患の治療および/または予防に適用される、
組成物。 - 下部小腸、回腸終末部、および/または結腸において特定の局所に有効であるように活性成分を制御放出および/または遅延放出する、経口投与のために製剤化された、請求項1に記載の組成物。
- ニコチン酸および/またはニコチンアミドを含む、請求項1または2に記載の組成物。
- 活性物質を制御放出および/または遅延放出する経口投与のために製剤化された請求項1から3のいずれか一項に記載の組成物。
- 結腸における直腸投与のために製剤化された請求項1から3のいずれか一項に記載の組成物。
- 1または2以上の物質に対して最終剤形あたり各1〜3000mgの活性物質含量で、好ましくは、1または2以上の物質に対して最終剤形あたり各10〜2500mgの活性物質含量での経口適用のために製剤化されることを特徴とする、請求項4に記載の組成物。
- 1または2以上の物質に対して最終剤形あたり各10〜5000mgの活性物質含量での経直腸適用のために製剤化されることを特徴とする、請求項5に記載の組成物。
- ニコチン酸および/またはニコチンアミドに加えて、アセチルサリチル酸および/またはプロスタグランジンD2拮抗薬および/またはスタチンが含まれることを特徴とする、請求項1から7のいずれか一項に記載の組成物。
- a)脂質代謝障害の治療および/または予防、
b)異脂肪血症の治療および/または予防、
c)肝臓脂肪含量を低減し、かつ/または血液および/もしくは血漿および/もしくは血清脂質レベルに有益に影響を及ぼすことによる、NAFLDの治療および/または予防、
d)肝臓脂肪含量を低減し、かつ/または血液および/もしくは血漿および/もしくは血清脂質レベルに有益に影響を及ぼすことによる、NASHの治療および/または予防、
e)心血管疾患の治療および/または予防、
f)動脈硬化症の治療および/または予防、
g)アテローム性動脈硬化症の治療および/または予防、
h)代謝症候群の治療および/または予防、
i)肥満の治療および/または予防、
からなる群から選択される1または2以上の治療および/または予防に適用される、請求項1に記載の組成物。 - 血液および/または血漿および/または血清脂質レベルに有益に影響を及ぼし、脂質代謝障害;異脂肪血症;NAFLD、およびNASHからなる群から選択される1または2以上の治療および/または予防に適用される、請求項1に記載の組成物。
- 下部小腸、回腸終末部、および/または結腸において局部的に有効であるように活性物質を放出するように製剤化され、
活性物質が循環系に侵入しないまたは低度にしか侵入せず、したがって活性物質および/またはその代謝産物の血液および/または血漿および/または血清レベルは、投薬前に測定したレベルより2ケタ、より好ましくは1ケタ高いレベルを超えない、請求項1から10のいずれか一項に記載の組成物。 - ニコチン酸もしくはニコチンアミド単独の制御放出および/もしくは遅延放出製剤である、またはニコチン酸の制御放出および/もしくは遅延放出製剤の、ニコチンアミドの制御放出および/もしくは遅延放出製剤との、可変用量の組合せもしくは固定用量の組合せである、請求項1から11のいずれか一項に記載の組成物。
- 高密度リポタンパク質(HDL)の血液レベルの増大のために、ならびに/あるいは、
異脂肪血症;NAFLD、および/またはNASHからなる群から選択される1または2以上の治療および/または予防のために、
ニコチン酸および/またはニコチンアミドが製剤化される、請求項1から12のいずれか一項に記載の組成物。 - ニコチン酸および/またはニコチンアミドが、単独で、および/またはそれらの可変用量の組合せもしくは固定用量の組合せで、スタチンとの可変用量の組合せまたは固定用量の組合せにおいて用いられる、請求項1から13のいずれか一項に記載の組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019103443A JP7387299B2 (ja) | 2013-12-13 | 2019-06-03 | ニコチン酸および/またはニコチンアミドを含む、腸内微生物叢を改変することにより血中脂質レベルに有益に影響を及ぼすための医薬組成物 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13197283.8 | 2013-12-13 | ||
EP13197283 | 2013-12-13 | ||
EP14154543 | 2014-02-10 | ||
EP14154543.4 | 2014-02-10 | ||
PCT/EP2014/077646 WO2015086843A2 (en) | 2013-12-13 | 2014-12-12 | A pharmaceutical composition containing nicotinic acid and/or nicotinamide for beneficially influencing blood lipid levels by modifying the intestinal microbiota |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019103443A Division JP7387299B2 (ja) | 2013-12-13 | 2019-06-03 | ニコチン酸および/またはニコチンアミドを含む、腸内微生物叢を改変することにより血中脂質レベルに有益に影響を及ぼすための医薬組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017500311A JP2017500311A (ja) | 2017-01-05 |
JP6895752B2 true JP6895752B2 (ja) | 2021-06-30 |
Family
ID=52021224
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016538751A Active JP6895752B2 (ja) | 2013-12-13 | 2014-12-12 | ニコチン酸および/またはニコチンアミドを含む、腸内微生物叢を改変することにより血中脂質レベルに有益に影響を及ぼすための医薬組成物 |
JP2019103443A Active JP7387299B2 (ja) | 2013-12-13 | 2019-06-03 | ニコチン酸および/またはニコチンアミドを含む、腸内微生物叢を改変することにより血中脂質レベルに有益に影響を及ぼすための医薬組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019103443A Active JP7387299B2 (ja) | 2013-12-13 | 2019-06-03 | ニコチン酸および/またはニコチンアミドを含む、腸内微生物叢を改変することにより血中脂質レベルに有益に影響を及ぼすための医薬組成物 |
Country Status (9)
Country | Link |
---|---|
US (1) | US10888555B2 (ja) |
EP (1) | EP3079675B1 (ja) |
JP (2) | JP6895752B2 (ja) |
DK (1) | DK3079675T3 (ja) |
ES (1) | ES2788866T3 (ja) |
HU (1) | HUE048488T2 (ja) |
PL (1) | PL3079675T3 (ja) |
PT (1) | PT3079675T (ja) |
WO (1) | WO2015086843A2 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2016007323A (es) | 2013-12-13 | 2016-09-09 | Conaris Res Inst Ag | Una composicion farmaceutica que contiene combinaciones de nicotinamida y acido 5-aminosalicilico para influir beneficiosamente en la microflora intestinal y/o para tratar la inflamacion gastrointestinal. |
KR20180135020A (ko) * | 2016-04-19 | 2018-12-19 | 훼링 비.브이. | 니코틴아미드의 경구 약제학적 조성물 |
CA3021071A1 (en) | 2016-04-19 | 2017-10-26 | Ferring B.V. | Oral pharmaceutical compositions of mesalazine |
RU2022101542A (ru) * | 2016-06-13 | 2022-02-03 | Сайньюрекс Интернэшнл (Тайвань) Корп. | Сокристаллы бензоата лития и их применения |
US11008277B2 (en) * | 2016-06-13 | 2021-05-18 | Syneurx International (Taiwan) Corp. | Co-crystals of sodium benzoate and uses thereof |
JPWO2018198842A1 (ja) * | 2017-04-23 | 2020-04-23 | 国立大学法人九州大学 | 非アルコール性脂肪性肝疾患用治療剤 |
EP3398600A1 (en) * | 2017-05-02 | 2018-11-07 | Salmon Pharma GmbH | Modified release nicotinamide |
EP3398601A1 (en) * | 2017-05-02 | 2018-11-07 | Salmon Pharma GmbH | Nicotinamide for treating dyslipidemia |
EP3703690A1 (en) * | 2017-10-30 | 2020-09-09 | Unilever N.V. | Use of niacinamide for microbiome balancing |
US20220249535A1 (en) * | 2019-04-05 | 2022-08-11 | Rejuvenation Therapeutics | Compositions comprising nicotinamide adenine dinucleotide-related compounds and use thereof |
CN113893262A (zh) * | 2021-09-29 | 2022-01-07 | 武汉英纽林生物科技有限公司 | 一种用于干预糖尿病前期空腹血糖偏高的nad+组合物及其制备方法和使用方法 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6129930A (en) * | 1993-09-20 | 2000-10-10 | Bova; David J. | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night |
US5846983A (en) | 1996-02-09 | 1998-12-08 | Mayo Foundation For Medical Education And Research | Colonic delivery of nicotine to treat inflammatory bowel disease |
US5736532A (en) | 1996-02-14 | 1998-04-07 | Furda; Ivan | Multifunctional fat absorption and blood cholesterol reducing formulation comprising chitosan |
GB9614902D0 (en) | 1996-07-16 | 1996-09-04 | Rhodes John | Sustained release composition |
US6713057B1 (en) * | 1999-02-24 | 2004-03-30 | The Johns Hopkins University | Compositions and methods for modulating serum cholesterol |
GB0015242D0 (en) | 2000-06-22 | 2000-08-16 | Nycomed Amersham Plc | Stabiliser for radiopharmaceuticals |
WO2002011725A1 (fr) | 2000-08-08 | 2002-02-14 | Shionogi & Co., Ltd. | Inhibiteurs de production de cytokine inflammatoire |
US20040185097A1 (en) | 2003-01-31 | 2004-09-23 | Glenmark Pharmaceuticals Ltd. | Controlled release modifying complex and pharmaceutical compositions thereof |
US20060264409A1 (en) | 2004-01-20 | 2006-11-23 | Harty Richard F | Compositions and methods of treatment for inflammatory diseases |
CA2553775A1 (en) | 2004-01-20 | 2005-08-11 | Richard F. Harty | Compositions and methods of treatment for inflammatory diseases |
CA2565993C (en) | 2004-05-27 | 2011-08-16 | Antibe Therapeutics Inc. | Salt of 4-or 5- aminosalicylic acid |
US20080020018A1 (en) | 2004-09-27 | 2008-01-24 | Joey Moodley | Combination Products |
WO2007004613A1 (ja) | 2005-07-01 | 2007-01-11 | Ajinomoto Co., Inc. | 炎症性腸疾患治療薬及びTNF-α産生抑制剤 |
ITMI20061932A1 (it) | 2006-10-09 | 2008-04-10 | Carlo Ghisalberti | Complessi a trasferimento di carica per uso medicale |
US20090104171A1 (en) | 2007-10-19 | 2009-04-23 | Pardee Joel D | Metabolic Enhancement Therapy |
EP2276491A4 (en) | 2008-04-25 | 2011-08-17 | Karolinska Inst Innovations Ab | NEW THERAPY FOR THE TREATMENT OF IRRITATION SYNDROME |
MX2010013169A (es) | 2008-06-02 | 2010-12-21 | Reddy S Lab Ltd | Formulaciones de niacina de liberacion modificada. |
EA022886B1 (ru) | 2008-10-03 | 2016-03-31 | Др. Фальк Фарма Гмбх | Способ поддержания ремиссии язвенного колита у пациентов |
JP2011121889A (ja) | 2009-12-09 | 2011-06-23 | En Otsuka Pharmaceutical Co Ltd | 炎症性腸疾患用アミノ酸組成物 |
JP2012102054A (ja) | 2010-11-11 | 2012-05-31 | Kyodo Milk Industry Co Ltd | 腸内ポリアミン増強剤 |
WO2012090224A1 (en) | 2010-12-29 | 2012-07-05 | Nutracryst Therapeutics Private Limited | Novel cocrystals / molecular salts of mesalamine to be used as improved anti-inflammatory drug |
HUE053359T2 (hu) | 2012-06-15 | 2021-06-28 | Conaris Res Institute Ag | Nikotinsavat és/vagy nikotinamidot és/vagy triptofánt tartalmazó gyógyászati készítmény a bél mikrobiótájának pozitív befolyásolására |
WO2014200347A1 (en) | 2013-06-14 | 2014-12-18 | Ferring B.V. | Extended release nicotinamide formulation |
MX2016007323A (es) | 2013-12-13 | 2016-09-09 | Conaris Res Inst Ag | Una composicion farmaceutica que contiene combinaciones de nicotinamida y acido 5-aminosalicilico para influir beneficiosamente en la microflora intestinal y/o para tratar la inflamacion gastrointestinal. |
KR20180135020A (ko) | 2016-04-19 | 2018-12-19 | 훼링 비.브이. | 니코틴아미드의 경구 약제학적 조성물 |
-
2014
- 2014-12-12 WO PCT/EP2014/077646 patent/WO2015086843A2/en active Application Filing
- 2014-12-12 JP JP2016538751A patent/JP6895752B2/ja active Active
- 2014-12-12 HU HUE14809908A patent/HUE048488T2/hu unknown
- 2014-12-12 EP EP14809908.8A patent/EP3079675B1/en active Active
- 2014-12-12 PL PL14809908T patent/PL3079675T3/pl unknown
- 2014-12-12 ES ES14809908T patent/ES2788866T3/es active Active
- 2014-12-12 DK DK14809908.8T patent/DK3079675T3/da active
- 2014-12-12 PT PT148099088T patent/PT3079675T/pt unknown
- 2014-12-12 US US15/103,410 patent/US10888555B2/en active Active
-
2019
- 2019-06-03 JP JP2019103443A patent/JP7387299B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
PL3079675T3 (pl) | 2020-07-27 |
DK3079675T3 (da) | 2020-04-20 |
PT3079675T (pt) | 2020-03-05 |
WO2015086843A2 (en) | 2015-06-18 |
HUE048488T2 (hu) | 2020-07-28 |
ES2788866T3 (es) | 2020-10-23 |
US10888555B2 (en) | 2021-01-12 |
JP7387299B2 (ja) | 2023-11-28 |
EP3079675B1 (en) | 2020-02-12 |
JP2019189616A (ja) | 2019-10-31 |
JP2017500311A (ja) | 2017-01-05 |
EP3079675A2 (en) | 2016-10-19 |
US20170027924A1 (en) | 2017-02-02 |
WO2015086843A3 (en) | 2015-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7387299B2 (ja) | ニコチン酸および/またはニコチンアミドを含む、腸内微生物叢を改変することにより血中脂質レベルに有益に影響を及ぼすための医薬組成物 | |
US20200009124A1 (en) | Pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
JP6554468B2 (ja) | ニコチンアミドと5−アミノサリチル酸との組合せを含有する、腸内微生物叢に有益な影響を及ぼすため、かつ/または胃腸の炎症を処置するため | |
EP3484449B1 (en) | Shellac microcapsule formulations and compositions for topical intestinal delivery of vitamin b3 | |
EP2884282A1 (en) | Use of tryptophan as a biomarker for patient selection, dosing and therapy monitoring for pharmaceutical compositions targeting the intestinal microbiota in diseases featuring tryptophan deficiency |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20170523 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171116 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180807 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20181102 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181227 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190205 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190603 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20190603 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20190611 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20190618 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20190705 |
|
C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20190709 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20200407 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20201006 |
|
C13 | Notice of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: C13 Effective date: 20201020 |
|
C302 | Record of communication |
Free format text: JAPANESE INTERMEDIATE CODE: C302 Effective date: 20201105 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210113 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210318 |
|
C23 | Notice of termination of proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C23 Effective date: 20210420 |
|
C03 | Trial/appeal decision taken |
Free format text: JAPANESE INTERMEDIATE CODE: C03 Effective date: 20210525 |
|
C30A | Notification sent |
Free format text: JAPANESE INTERMEDIATE CODE: C3012 Effective date: 20210525 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210608 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6895752 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |